A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment

PHASE4CompletedINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions
Mild Cognitive Impairment
Interventions
DRUG

Aricept (donepezil hydrochloride)

5 mg or 10 mg of donepezil hydrochloride (Aricept) taken orally once a day.

DRUG

placebo

Trial Locations (49)

10016

New York University School of Medicine Aging and Dementia Research Center, New York

10032

Columbia University, New York

10305

Behavioral Medical Research of Staten Island, Staten Island

11559

Neurobehavioral Research Inc., Lawrence

12208

Neurological Associates of Albany, PC Neurology, Albany

14620

Monroe Community Hospital Program in Neurobehavioral Therapeutics, Rochester

15601

Westmoreland Neurology Associates, Greensburg

19004

Clinical Trial Specialists, Bala-Cynwyd

19046

The Clinical Trial Center, LLC, Jenkintown

29406

Medical University of South Carolina-Alzheimer's Research, Charleston

33016

Berma Research Group, Hialeah

33021

Sunrise Clinical Research, Hollywood

33064

North Broward Medical Center Memory Disorder Center, Deerfield Beach

33140

Wien Center for Memory Disorders, Mount Sinai Medical Center, Miami Beach

33308

Neurologic Consultants, Fort Lauderdale

33317

Berma Research Group, Plantation

33407

Palm Beach Neurology, West Palm Beach

33613

Stedman Clinical Trials, LLC, Tampa

USF Memory Disorder's Clinic, Tampa

33617

USF Suncoast Gerontalogy Center, Tampa

33702

Comprehensive Neuroscience, Inc., St. Petersburg

34243

The Roskamp Institute, Sarasota

34285

Center for Clinical Trials. L.C., Venice

35007

Neurology Neurodiagnostic Lab, LLC, Alabaster

40504

Lexington Clinic, Lexington

43210

The Ohio State University, Columbus

43623

Neurology Center of Ohio, Toledo

49048

Borgess Research Institute, Kalamazoo

63104

St. Louis University - Clinical Trials Unit, St Louis

73118

Pahl Pharmaceutical Research, LLC, Oklahoma City

76309

Grayline Clinical Drug Trials, Wichita Falls

77030

The University of Texas Mental Sciences Instittute, Houston

85351

Sun Health Research Institute, Sun City

85381

Pivotal Research Centers, Peoria

90404

Neurological Research Institute, Santa Monica

91403

CA Neuroscience Research, Sherman Oaks

91942

Optimum Health Services, La Mesa

92024

The Neurology Center, Encinitas

92081

Pacific Research Network, Vista

92103

Pacific Research Network, San Diego

92618

Nerve Pro Research, Irvine

92845

Colaborative Neuroscience Network (CNS Network), Garden Grove

93720

Margolin Brain Institute, Fresno

97210

Summit Research Network(Oregon) Inc., Portland

85741-3537

Northwest Neurospecialists, PLLC, Tucson

06510

Yale University Alzheimers Disease Research Unit School of Medicine Department of Psychiatry, New Haven

07033

Comprehensive Neuroscience, Inc, Kenilworth

78229-3900

START Center, San Antonio

05201

Southwestern Vermont Medical Center - The Memory Clinc, Bennington

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT00934375 - A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment | Biotech Hunter | Biotech Hunter